{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:39:34Z","timestamp":1792517974176,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015285","name":"Hebei Province Medical Science Research Key Project","doi-asserted-by":"publisher","award":["20220159"],"award-info":[{"award-number":["20220159"]}],"id":[{"id":"10.13039\/501100015285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015285","name":"Hebei Province Medical Science Research Key Project","doi-asserted-by":"publisher","award":["20230781"],"award-info":[{"award-number":["20230781"]}],"id":[{"id":"10.13039\/501100015285","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejso.2026.112211","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:15:25Z","timestamp":1791904525000},"page":"112211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of baseline tumour length in oesophageal squamous cell carcinoma patients treated with neoadjuvant immunochemotherapy"],"prefix":"10.1016","volume":"53","author":[{"given":"Dandan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.112211_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejso.2026.112211_bib2","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.ejso.2026.112211_bib3","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1186\/s12885-023-11747-9","article-title":"Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)","volume":"23","author":"Ding","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2026.112211_bib4","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2026.112211_bib5","article-title":"Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): a randomized, open, phase \u2161 study","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112211_bib6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s40001-025-02599-z","article-title":"Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice: an analysis of the clinical outcomes and long-term survival, and the feasibility of using major pathological response as a surrogate endpoint","volume":"30","author":"Liu","year":"2025","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ejso.2026.112211_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00262-025-04168-z","article-title":"Impact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study","volume":"74","author":"Huang","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejso.2026.112211_bib8","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1186\/s12885-021-08728-1","article-title":"Prognostic impact of tumor length in esophageal cancer: a systematic review and meta-analysis","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2026.112211_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153068","article-title":"Endoscopic tumor length should be reincluded in the esophageal cancer staging system: analyses of 662 consecutive patients","volume":"11","author":"Valmasoni","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2026.112211_bib10","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejso.2026.112211_bib11","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.athoracsur.2010.11.011","article-title":"Tumor length as a prognostic factor in esophageal squamous cell carcinoma","volume":"91","author":"Wang","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ejso.2026.112211_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1456193","article-title":"Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study","volume":"15","author":"Feng","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejso.2026.112211_bib13","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejso.2026.112211_bib14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1186\/s12885-025-14686-9","article-title":"Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma","volume":"25","author":"Mao","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2026.112211_bib15","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1186\/s12967-025-07158-y","article-title":"Pathological responses to neoadjuvant immunochemotherapy: implications for survival and recurrence in patients with locally advanced esophageal squamous cell carcinoma","volume":"23","author":"Li","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejso.2026.112211_bib16","article-title":"Recurrence patterns and adjuvant therapy strategies in patients with esophageal squamous cell carcinoma who achieved pathological complete response after neoadjuvant immunochemotherapy: a high-volume retrospective study","volume":"52","author":"Zhu","year":"2025","journal-title":"EJSO-EUR J SURG ONC"},{"key":"10.1016\/j.ejso.2026.112211_bib17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2023.03.008","article-title":"Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma","volume":"186","author":"Wang","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2026.112211_bib18","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jtcvs.2025.06.012","article-title":"A pathologic classification approach in esophageal squamous cell carcinoma following neoadjuvant immunochemotherapy: distinguishing postoperative outcomes and exploring the potential benefit of adjuvant therapy","volume":"170","author":"Lin","year":"2025","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejso.2026.112211_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00262-025-04168-z","article-title":"Impact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study","volume":"74","author":"Yan","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejso.2026.112211_bib20","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1245\/s10434-008-0084-y","article-title":"Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response","volume":"15","author":"Barbour","year":"2008","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326008309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326008309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:58:04Z","timestamp":1792515484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326008309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S0748798326008309"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112211","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of baseline tumour length in oesophageal squamous cell carcinoma patients treated with neoadjuvant immunochemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112211"}}